{"filing":{"accession_number":"0001193125-26-329618","cik":"0001625297","ticker":"INDV","company_name":"Indivior Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"d166865d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1625297/000119312526329618/d166865d8k.htm"},"events":[{"id":23324,"run_id":21090,"accession_number":"0001193125-26-329618","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"The filing discloses execution of an \"Agreement and Plan of Merger, dated August 1, 2026, by and among Indivior, Supernus and Artemis Merger Sub Inc.\" This is a material acquisition/merger transaction combining two pharmaceutical companies into a $2.2 billion CNS biopharmaceutical leader. The transaction structure, ownership split (56.5% Indivior / 43.5% Supernus shareholders), governance, and expected synergies of $125 million are all detailed, making this a clear ma_activity event.","company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23522,"accession_number":"0001193125-26-329618","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses execution of an \"Agreement and Plan of Merger, dated August 1, 2026, by and among Indivior, Supernus and Artemis Merger Sub Inc.\" This is a material acquisition/merger transaction combining two pharmaceutical companies into a $2.2 billion CNS biopharmaceutical leader. The transaction structure, ownership split (56.5% Indivior / 43.5% Supernus shareholders), governance, and expected synergies of $125 million are all detailed, making this a clear ma_activity event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:19:55.227738+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23522,"accession_number":"0001193125-26-329618","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses execution of an \"Agreement and Plan of Merger, dated August 1, 2026, by and among Indivior, Supernus and Artemis Merger Sub Inc.\" This is a material acquisition/merger transaction combining two pharmaceutical companies into a $2.2 billion CNS biopharmaceutical leader. The transaction structure, ownership split (56.5% Indivior / 43.5% Supernus shareholders), governance, and expected synergies of $125 million are all detailed, making this a clear ma_activity event.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:19:55.227738+00:00","company_name":"Indivior Pharmaceuticals, Inc.","ticker":"INDV","filing_date":"2026-08-03"}]}